183 related articles for article (PubMed ID: 37868976)
1. Efficient and stable CRISPR/Cas9-mediated genome-editing of human type 2 innate lymphoid cells.
Audouze-Chaud J; Mathews JA; Crome SQ
Front Immunol; 2023; 14():1275413. PubMed ID: 37868976
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells.
Riggan L; Hildreth AD; Rolot M; Wong YY; Satyadi W; Sun R; Huerta C; O'Sullivan TE
Cell Rep; 2020 May; 31(7):107651. PubMed ID: 32433960
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Genome Editing of Primary Human Vascular Cells In Vitro.
Atri DS; Lee-Kim VS; Vellarikkal SK; Sias-Garcia O; Yanamandala M; Schniztler GR; Gupta RM
Curr Protoc; 2021 Nov; 1(11):e291. PubMed ID: 34748284
[TBL] [Abstract][Full Text] [Related]
5. Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells.
Ebihara T
Cells; 2020 May; 9(5):. PubMed ID: 32403291
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Primary Innate Immune Cells.
Hildreth AD; Riggan L; O'Sullivan TE
STAR Protoc; 2020 Dec; 1(3):100113. PubMed ID: 33377009
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of NK Cells and Other Innate Lymphoid Cells in Human and Murine Decidua.
Vacca P; Chiossone L; Mingari MC; Moretta L
Front Immunol; 2019; 10():170. PubMed ID: 30800126
[TBL] [Abstract][Full Text] [Related]
8. Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice.
Alisjahbana A; Mohammad I; Gao Y; Evren E; Ringqvist E; Willinger T
Biochem Pharmacol; 2020 Apr; 174():113672. PubMed ID: 31634458
[TBL] [Abstract][Full Text] [Related]
9. Helper-like Innate Lymphoid Cells in Humans and Mice.
Guia S; Narni-Mancinelli E
Trends Immunol; 2020 May; 41(5):436-452. PubMed ID: 32223931
[TBL] [Abstract][Full Text] [Related]
10. Improved CRISPR/Cas9 gene editing in primary human myoblasts using low confluency cultures on Matrigel.
Goullée H; Taylor RL; Forrest ARR; Laing NG; Ravenscroft G; Clayton JS
Skelet Muscle; 2021 Sep; 11(1):23. PubMed ID: 34551826
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.
Oh SA; Seki A; Rutz S
Curr Protoc Immunol; 2019 Feb; 124(1):e69. PubMed ID: 30334617
[TBL] [Abstract][Full Text] [Related]
12. Brain endothelial CXCL12 attracts protective natural killer cells during ischemic stroke.
Wang S; de Fabritus L; Kumar PA; Werner Y; Ma M; Li D; Siret C; Simic M; Li B; Kerdiles YM; Hou L; Stumm R; van de Pavert SA
J Neuroinflammation; 2023 Jan; 20(1):8. PubMed ID: 36631780
[TBL] [Abstract][Full Text] [Related]
13. Innate lymphoid cells in atherosclerosis.
Engelbertsen D; Lichtman AH
Eur J Pharmacol; 2017 Dec; 816():32-36. PubMed ID: 28449862
[TBL] [Abstract][Full Text] [Related]
14. Innate Lymphoid Cells in the Maternal and Fetal Compartments.
Miller D; Motomura K; Garcia-Flores V; Romero R; Gomez-Lopez N
Front Immunol; 2018; 9():2396. PubMed ID: 30416502
[TBL] [Abstract][Full Text] [Related]
15. Innate lymphoid cells: from helper to killer.
Krabbendam L; Bernink JH; Spits H
Curr Opin Immunol; 2021 Feb; 68():28-33. PubMed ID: 32971468
[TBL] [Abstract][Full Text] [Related]
16. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice.
Montaldo E; Juelke K; Romagnani C
Eur J Immunol; 2015 Aug; 45(8):2171-82. PubMed ID: 26031799
[TBL] [Abstract][Full Text] [Related]
17. CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway.
Chen L; Youssef Y; Robinson C; Ernst GF; Carson MY; Young KA; Scoville SD; Zhang X; Harris R; Sekhri P; Mansour AG; Chan WK; Nalin AP; Mao HC; Hughes T; Mace EM; Pan Y; Rustagi N; Chatterjee SS; Gunaratne PH; Behbehani GK; Mundy-Bosse BL; Caligiuri MA; Freud AG
Immunity; 2018 Sep; 49(3):464-476.e4. PubMed ID: 30193847
[TBL] [Abstract][Full Text] [Related]
18. Non-cytotoxic Cardiac Innate Lymphoid Cells Are a Resident and Quiescent Type 2-Commited Population.
Bracamonte-Baran W; Chen G; Hou X; Talor MV; Choi HS; Davogustto G; Taegtmeyer H; Sung J; Hackam DJ; Nauen D; Čiháková D
Front Immunol; 2019; 10():634. PubMed ID: 30984196
[TBL] [Abstract][Full Text] [Related]
19. The Metabolic Basis of ILC Plasticity.
Pelletier A; Stockmann C
Front Immunol; 2022; 13():858051. PubMed ID: 35572512
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of Natural Killer Cells and Other Innate Lymphoid Cells.
Cong J
Front Immunol; 2020; 11():1989. PubMed ID: 32983138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
